Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
MALLINCKRODT INC. V. WATSON LABORATORIES, INC.-FLORIDA
Case Number:
2:10-cv-06424
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
January 25, 2012
Covidien Makes Deal With Watson To Allow Generic Exalgo
Zalicus Inc. on Wednesday said Covidien PLC, with which it partners on Covidien's painkiller Exalgo, has agreed to a settlement with Watson Pharmaceuticals Inc. that will allow a generic version of Exalgo to hit the market before the expiration of Covidien's patent.
-
December 15, 2010
Covidien Unit Targets Watson Over Generic Exalgo
A Covidien PLC subsidiary has sued specialty pharmaceutical company Watson Pharmaceuticals Inc. in an effort to stop it from marketing a generic version of painkiller Exalgo.